# Comparative Bioavailability Study of Synerx and Verelan PM 300 mg Verapamil HCl ER Capsules Under Fed Conditions

> **NCT01467687** · PHASE1 · COMPLETED · sponsor: **Synerx Pharma, LLC** · enrollment: 58 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** verapamil controlled release

## Key facts

- **NCT ID:** NCT01467687
- **Lead sponsor:** Synerx Pharma, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2007-08
- **Final completion:** 2007-08
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2011-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01467687

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01467687, "Comparative Bioavailability Study of Synerx and Verelan PM 300 mg Verapamil HCl ER Capsules Under Fed Conditions". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01467687. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*